GleamWall
中文EN

CUPR Cuprina Holdings (Cayman) LTD Annual reports only

Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1995704 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY9.2%
TTM net income YoY-216.7%
TTM EPS YoY-178.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-1.3%
Operating margin-9,680.1%
Net margin-9,366.7%
FCF margin-18,423.3%
EBITDA margin-9,606.9%

Returns

ROE-1,115.0%
ROA-92.0%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets40.6%
Debt / equity0.03x
Current ratio2.35x
Interest coverage-328.02x

Cash quality & payout

Operating cash flow / net income1.95x
Accruals ratio87.9%
Payout ratio—
Capex / revenue116.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31 · USDFY20242024-12-31 · USDFY20232023-12-31 · SGDFY20222022-12-31 · SGD
Income statement
Revenue$38,789$35,522100,77356,599
Cost of revenue$39,290$37,74564,16836,621
Gross profit-$501-$2,22336,60519,978
R&D expense$176,385$177,433167,734292,879
SG&A expense$3.58M$1.03M937,200902,887
Operating income-$3.75M-$1.21M-1.07M-1.18M
Interest expense$11,447$1,3117271,842
Pretax income-$3.58M-$1.11M-1.09M-1.09M
Net income-$3.63M-$1.15M-1.12M-1.09M
EBITDA-$3.73M-$1.18M-1.03M-1.15M
EPS (basic)-17.75-6.38-6.22-6.08
EPS (diluted)-17.75-6.38-6.22-6.08
Weighted avg. shares (diluted)20.47M18.00M18.00M18.00M
Banking
Net interest income-$11,447-$27,354-56,587-2,017
Provision for credit losses-$2,960-$1,553106-2,935
Balance sheet
Cash & equivalents$2.42M$85,62235,263—
Receivables$14,163$19,39950,819—
Inventory—$1,2727,665—
Current assets$5.70M$1.22M1.44M—
PP&E, net$60,270$42,68578,366—
Total assets$6.61M$1.28M1.59M—
Current liabilities$2.42M$4.44M4.43M—
Short-term debt$30,108$40,616——
Long-term debt$98,112$120,362——
Total debt$128,220$160,978——
Total liabilities$2.68M$4.56M4.48M—
Shareholders' equity$3.93M-$3.28M-2.99M-1.78M
Net debt-$2.30M$75,356——
Cash flow statement
Operating cash flow-$7.10M-$908,609-894,981-1.85M
Capital expenditure$45,268$16,08867,97716,049
Free cash flow-$7.15M-$924,697-962,958-1.87M
Investing cash flow-$45,268-$16,088-67,977-31,284
Financing cash flow$9.51M$985,795433,0751.68M
Depreciation & amortization$28,394$31,01235,05929,088

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.